BRPI0520821A2 - formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada - Google Patents

formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada

Info

Publication number
BRPI0520821A2
BRPI0520821A2 BRPI0520821-1A BRPI0520821A BRPI0520821A2 BR PI0520821 A2 BRPI0520821 A2 BR PI0520821A2 BR PI0520821 A BRPI0520821 A BR PI0520821A BR PI0520821 A2 BRPI0520821 A2 BR PI0520821A2
Authority
BR
Brazil
Prior art keywords
fenofibrate
pharmaceutical formulations
improved bioavailability
polyethylene
fenofibrate pharmaceutical
Prior art date
Application number
BRPI0520821-1A
Other languages
English (en)
Portuguese (pt)
Inventor
E Itzhak Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0520821A2 publication Critical patent/BRPI0520821A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
BRPI0520821-1A 2005-12-28 2005-12-28 formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada BRPI0520821A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/047346 WO2007075171A1 (fr) 2005-12-28 2005-12-28 Formulations pharmaceutiques de fénofibrate ayant une biodisponibilité améliorée

Publications (1)

Publication Number Publication Date
BRPI0520821A2 true BRPI0520821A2 (pt) 2009-06-30

Family

ID=36499668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520821-1A BRPI0520821A2 (pt) 2005-12-28 2005-12-28 formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada

Country Status (7)

Country Link
JP (1) JP2009522258A (fr)
CN (1) CN101351191A (fr)
BR (1) BRPI0520821A2 (fr)
CA (1) CA2634094A1 (fr)
IL (1) IL192230A0 (fr)
MX (1) MX2008008589A (fr)
WO (1) WO2007075171A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029181A1 (fr) * 2009-09-09 2011-03-17 Bernard Charles Sherman Compositions de fénofibrate de choline à libération retardée
ES2826224T3 (es) * 2013-03-14 2021-05-17 Aimmune Therapeutics Inc Fabricación de formulaciones de maní para desensibilización oral
KR101850119B1 (ko) 2015-11-11 2018-04-20 제이투에이치바이오텍 (주) 생체이용률이 향상된 신규한 페노피브르산 전구약물
EP3965815A4 (fr) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. Procédés d'amélioration de la qualité de vie d'un patient souffrant d'allergie à l'arachide
CN112618511A (zh) * 2020-12-31 2021-04-09 辰欣药业股份有限公司 一种非诺贝特胶囊的处方组成及制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
MXPA04009385A (es) * 2002-03-26 2005-01-25 Teva Pharma Microparticulas de drogas.
CA2540984C (fr) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S Forme de dose solide comprenant un fibrate
BRPI0415121A (pt) * 2003-10-10 2006-11-28 Lifecycle Pharma As material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida

Also Published As

Publication number Publication date
CN101351191A (zh) 2009-01-21
WO2007075171A1 (fr) 2007-07-05
CA2634094A1 (fr) 2007-07-05
MX2008008589A (es) 2009-02-25
IL192230A0 (en) 2008-12-29
JP2009522258A (ja) 2009-06-11

Similar Documents

Publication Publication Date Title
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008008364A3 (fr) Compositions liquides de phényléphrine à stabilité améliorée
GT199900203A (es) Composiciones de celecoxib.
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0620229A8 (pt) formulação
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BRPI0510422A (pt) formulação cosmética transparente à base de microemulsões contendo um ácido alfa-hidroxicarboxìlico
NI201100076A (es) Péptidos antivirales terapéuticos.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
BRPI0520821A2 (pt) formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
NO20064808L (no) Orale matrixformuleringer med licarbazepin
CY1109209T1 (el) Μητρες ανιονικης υδρογελης με ph-εξαρτωμενη τροποιημενη αποδεσμευση ως μεταφορεις φαρμακων
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.